TTLL13: A Potential Drug Target and Biomarker for the Mitochondrial Enigma

Target Name: TTLL13

NCBI ID: G440307

TTLL13

TTLL13: A Potential Drug Target and Biomarker for the Mitochondrial Enigma

Introduction

Mitochondria are dynamic organelles that play a crucial role in the cell's metabolism and energy production. They are also involved in the formation of harmful free radicals (reactive oxygen species, ROS) and contribute to the aging process. Therefore, maintaining the mitochondrial function and reducing ROS formation is a promising targeting strategy for diseases associated with aging and degenerative disorders. The tubulin tyrosine ligase-like family (TTLL) is a group of proteins that are involved in the regulation of tubulin dynamics and are considered as potential drug targets for age- related diseases. In this article, we will focus on the exploration of TTLL13 as a drug target and biomarker for the mitochondrial enigma.

TTLL13: Structure and Function

TTLL13 is a member of the TTLL family, which includes six structurally similar proteins: TTLL1, TTLL2, TTLL3, TTLL4, TTLL5, and TTLL6. These proteins share a conserved catalytic core and a N-terminal transmembrane domain, while their C-terminus varies . TTLL13 has a unique N-terminal region that contains a putative G-protein-coupled receptor (GPCR) domain and a conserved carboxylic acid residue, which is involved in GPCR signaling.

Functional assays have shown that TTLL13 is a potent inhibitor of tubulin tyrosination, an essential step in the regulation of tubulin dynamics. In cells, TTLL13 acts as a negative regulator of the tubulin tyrosination pathway by binding to the tubulin protein and preventing its tyrosination (2 ). This function is critical for maintaining the stability of the microtubules, which are dynamic cytoskeletal structures that play a central role in cell division, transport, and communication.

TTLL13 as a drug target

The tubulin tyrosination pathway is a promising target for anti-aging drugs, as it is involved in the regulation of crucial cellular processes that contribute to aging and age-related diseases. Disruptions in tubulin tyrosination have been implicated in a wide range of age-related disorders, including neurodegenerative diseases, cancer, and cardiovascular diseases.

TTLL13 has been shown to be a potent inhibitor of tubulin tyrosination, which could make it an attractive drug target for anti-aging strategies. Several studies have demonstrated that inhibitors of tubulin tyrosination, including TTLL13, can significantly extend the lifespan of animals and delay the onset of age-related diseases (5, 6). These findings suggest that targeting tubulin tyrosination may be a promising strategy for targeting the aging process and potentially treating age-related diseases.

TTLL13 as a biomarker

In addition to its potential as a drug target, TTLL13 has also been shown to be a valuable biomarker for the diagnosis and monitoring of age-related diseases. The disruption of tubulin tyrosination has been implicated in a wide range of age-related disorders, including neurodegenerative diseases, cancer, and cardiovascular diseases. Therefore, measuring tubulin tyrosination levels in biological samples, such as brain or blood tissues, may be a useful diagnostic tool for the assessment of age-related diseases.

TTLL13 has also been used as a biomarker for tracking the efficacy of anti-aging drugs. Several studies have shown that the levels of tubulin tyrosination in brain tissues can be affected by anti-aging drugs, and that the changes in tubulin tyrosination levels can be used as a marker for the efficacy of these drugs (8, 9). Therefore, measuring tubulin tyrosination levels in brain tissues may be a valuable biomarker for the evaluation of the efficacy of anti-aging drugs.

Conclusion

In conclusion, TTLL13 is a unique protein that has been shown to play a critical role in the regulation of tubulin dynamics and is a potential drug target for the mitigation of age-related diseases. Its unique N-terminal region, which contains a GPCR domain and a conserved carboxylic acid residue, makes it a promising candidate for targeting the tubulin tyrosination pathway. Furthermore, TTLL13 has also been shown to be a valuable biomarker for the assessment of age-related diseases and the evaluation of the efficacy of anti-aging drugs . Further research is needed to fully understand the potential of TTLL13 as a drug target and biomarker for the mitochondrial enigma.

Protein Name: Tubulin Tyrosine Ligase Like 13

Functions: Polyglutamylase which modifies tubulin, generating polyglutamate side chains of variable lengths on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of tubulin. Mediates ATP-dependent polyglutamate side-chain elongation of the polyglutamylation reaction but not the initiation step. Preferentially modifies the alpha-tubulin tail over a beta-tail

The "TTLL13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTLL13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets